GC
TRIL

Gratus Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Gratus Capital’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-40,000
Closed -$162K – 184
2020
Q1 		$162K Buy
+40,000
New +$151K 0.03% 158

Other funds holding TRIL

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gratus Capital's TRIL Position: Q2 2020 in Review

Gratus Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q2 2020, closing a stake of 40,000 shares — an estimated $162K sold.

Gratus Capital first reported a position in TRIL in Q1 2020 and held it in 1 quarter. The position peaked at $162K in Q1 2020. 84 funds tracked by Wall St. Rank hold TRIL as of Q2 2020.

  • Gratus Capital reported no remaining Trillium Therapeutics Inc. position as of Q2 2020 after selling out during the quarter.
  • Gratus Capital sold 40,000 Trillium Therapeutics Inc. shares in Q2 2020, an estimated $162K.
  • Gratus Capital first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 1 quarter.
  • Gratus Capital's Trillium Therapeutics Inc. position peaked at $162K in Q1 2020.
  • 84 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q2 2020.

Based on Gratus Capital's 13F filing for Q2 2020, filed 11 Aug 2020.